CAT uses Hogarth for AZ deal

Cambridge Antibody Technology (CAT) – the British biotech firm to be acquired by AstraZeneca in a deal valued at £702m – is using The Hogarth Partnership for comms advice.

CAT developed rheumatoid arthritis treatment Humira, the first British biotech ‘blockbuster’, which saw sales of more than $1.4bn (£745m) in 2005.

Since November 2003, AZ has owned 19.2 per cent of CAT, and the two companies work together on projects. In a deal confirmed this week, AZ is now to take full control of the company.

Hogarth managing partner Chris Matthews told PRWeek: ‘This deal is attractive to AZ because CAT will become a semi-autonomous unit within AstraZeneca, and will be kept as a centre for research.’

After the deal is completed, CAT will no longer be a public company. Therefore Hogarth’s job will be to inform scientific and business audiences of the company’s progress, particularly because CAT plans to continue its collaboration with various organisations.

Weber Shandwick worked with CAT for four years until April last year.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in